Jill Zitzewitz, PhD is an associate professor in academic medicine. She spent her career studying therapeutic development for protein misfolding diseases. Since being diagnosed with multiple myeloma in 2017, Jill has been teaching fulltime while providing a patient’s perspective through her experiences with multiple myeloma. Current myeloma therapies have allowed her to continue teaching and to be a mother to four young adults.  In 2020, Jill became the leader for the central MA multiple myeloma support group of the IMF.  This is the first time that Jill will be attending the ASH Conference as a patient advocate rather than as a scientific researcher. She plans to use her background in science and education to help patients understand the important impact of new and novel therapies for treating multiple myeloma. 

Follow Jill on Twitter: @JillZitzewitz
Support Group Website: Central MA Multiple Myeloma Support Group

 

We’re Here for You!

We’re Here for You!

Day 3 of ASH was another whirlwind of talks, and even for this scientist, all the details were beginning to blur together. I heard talks that ranged in focus (1) from understanding the molecular basis of disease; (2) to delineating the role of precursor conditions in myeloma progression; (3) to developing the best diagnostic approaches to track disease; (4) to analyzing clinical trial outcomes in order to measure therapy effectiveness. Throughout the day, I found myself noticing a common theme...

read more
It’s All About Antibodies and Your Amazing Bone Marrow

It’s All About Antibodies and Your Amazing Bone Marrow

Today was another great day at ASH21, and antibodies (of course) took center stage in my choice of talks to attend.  Darzalex® (daratumumab), again, showed impressive results, this time in the ADROMENA trial for light-chain (AL) amyloidosis — a protein misfolding disease that can also occur in ~15% of multiple myeloma patients. These phase III trial results that were presented by Dr. Raymond Comenzo, MD, showed that the addition of Darzalex to Velcade/Cytoxin/dexamethasone (VCd) induction...

read more
The Amazing Power of Proteins (and RNAs too)

The Amazing Power of Proteins (and RNAs too)

In my scientific career as a protein scientist studying protein misfolding, I’ve always been a little protein-centric in my view of biology. It’s a bit ironic because I work at an academic institution that is an RNA mecca, where many of my colleagues are doing amazing research understanding the role of RNAs in biology.   Simplistically, proteins do all the work in the cell. DNA gets all the glory, but RNA is the master regulator controlling the fate...

read more
Pre-ASH Blog: From Academic to Advocate

Pre-ASH Blog: From Academic to Advocate

My prior identity as a scientist often flows uneasily with my new identity as a multiple myeloma patient advocate. In my career as a scientist in academic medicine, I’ve attended many national and international meetings where I’ve presented my research on protein misfolding. I’ve always loved the excitement of new ideas and the connections between scientists at meetings working toward a common goal.   Five years ago, I attended an RNA biology meeting in San Diego and had trouble...

read more